BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
10.27
-0.76 (-6.89%)
NASDAQ · Last Trade: May 6th, 10:32 PM EDT
Detailed Quote
Previous Close
11.03
Open
10.97
Bid
10.21
Ask
10.35
Day's Range
10.10 - 10.97
52 Week Range
4.750 - 11.11
Volume
14,478,437
Market Cap
1.91B
PE Ratio (TTM)
-23.88
EPS (TTM)
-0.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,407,225
Chart
About BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
Biocryst Pharma is a biotechnology company focused on developing and commercializing innovative treatments for rare diseases. The company specializes in designing and synthesizing novel small-molecule drugs, particularly those targeting diseases associated with viral infections and genetic disorders. With a commitment to improving patient outcomes, Biocryst employs cutting-edge research and clinical development strategies to bring effective therapies to market, aiming to address unmet medical needs in challenging therapeutic areas. Read More
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases. Customers are increasingly seeking antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are easy to administer and have a shorter treatment duration. The Antiviral Drugs segment is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs. A report from Statista said that: “The projected revenue in the Antiviral Drugs market worldwide is estimated to reach US$51.18bn in 2024. It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.58%, leading to a market volume of US$55.36bn by 2029. In terms of global comparison, United States is anticipated to generate the highest revenue, with US$30,640.00m in 2024. In the worldwide market for antiviral drugs, the United States leads in research and development, driving innovation and setting industry standards.” Active Biotechs in the biotech markets today include: NanoViricides, Inc. (NYSE: NNVC), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Veru Inc. (NASDAQ: VERU), Chimerix (NASDAQ: CMRX), SIGA Technologies, Inc. (NASDAQ: SIGA).
Insiders are buying these stocks that should be on your radar, but only two are set up to rebound and move higher today; the third may move lower first.
